Kalaris Therapeutics (KLRS) director Ferrara received 9,000 Stock Option (Right to Buy)
Stocks in this Quantisnow insightHealth Care
Insider transactions reported
Napoleone Ferrara (director at Kalaris Therapeutics Inc., KLRS) reported that they received 9,000 Stock Option (Right to Buy) on Jun 3, 2026.
- Reporting person
- Ferrara Napoleone
Options and other derivatives
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| Jun 3, 2026 | Grant or award (A) | Stock Option (Right to Buy)On 9,000 Common Stock1 | +9,000 | - | - | 9,000 direct |
Holdings before and after
- Stock Option (Right to Buy): 0 to 9,000 direct
Footnotes from the filing
- 1. The option was granted on June 3, 2026. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 3, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to continued service.
Transaction codes in this filing
- Grant or award:
- Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.
FAQ
What did Ferrara report in this KLRS Form 4?
Napoleone Ferrara (director at Kalaris Therapeutics Inc., KLRS) reported that they received 9,000 Stock Option (Right to Buy) on Jun 3, 2026.
What does transaction code A mean on an SEC Form 4?
Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.
Historical context for KLRS
Across the 9 sessions after earlier KLRS headlines, the stock closed higher 3 times and lower 5 times, with a median move of 2.7% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | KLRS | SPY |
|---|---|---|---|
| May 14, 2026 | Wedbush initiated coverage on Kalaris Therapeutics with a new price target | +8.1% | +0.8% |
| May 12, 2026 | Kalaris Reports First Quarter 2026 Financial Results and Provides Business Updates | +1.3% | -0.2% |
| Apr 16, 2026 | Morgan Stanley initiated coverage on Kalaris Therapeutics with a new price target | +12.3% | +0.2% |
| Mar 17, 2026 | Kalaris Reports Full Year 2025 Financial Results and Provides Business Updates | -3.3% | +0.3% |
| Jan 29, 2026 | Kalaris to Present Phase 1 Clinical Data for TH103 at the Macula Society Annual Meeting | -2.6% | -0.2% |
| Dec 23, 2025 | Chardan Capital Markets initiated coverage on Kalaris Therapeutics with a new price target | -4.0% | +0.5% |
Earlier insider filings at KLRS
- Jun 4, 2026SEC Form 4 filed by Director Hallal David
- Jun 4, 2026SEC Form 4 filed by Director Akkaraju Srinivas
- Jun 4, 2026SEC Form 4 filed by Director Dybbs Michael
- Jun 4, 2026SEC Form 4 filed by Director Adamis Anthony P
- Jun 4, 2026SEC Form 4 filed by Director Patterson Leone D
Keep researching KLRS
- KLRS insider tradesEvery buy and sale reported by Kalaris Therapeutics Inc. officers, directors and large holders.
- What is Form 4?The SEC filing that reports a change in an insider's holdings, such as a purchase, sale, option exercise or grant, generally within two business days.
- Form 4 explainedForm 4 is the SEC filing that discloses when officers, directors and 10% owners buy or sell company stock, due within 2 business days. Learn every key field and code.
- Insider trading trackerThe latest insider buys and sales across every stock.
- KLRS financial statementsRevenue, profit, cash flow and balance sheet from Kalaris Therapeutics Inc.'s SEC filings.
Quantisnow market dataNASDAQ
KLRS
Kalaris Therapeutics Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Listed since
- 2020
Get push alerts for KLRS
Full KLRS profile on Quantisnow Follow KLRS and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time